kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human protein kinase WEE1, 10 µg  

Recombinant human protein kinase WEE1, 10 µg

Recombinant human Wee1 protein kinase, WEE1 G 2 checkpoint kinase (amino acids Q250-Y64), GST-HIS6 fusion protein, expressed in Sf9 cells

Synonyms: recombinant, human, protein kinase, WEE1, WEE1A, WEE1hu, WEE1 G2 checkpoint kinase

More details


Availability: on stock

295,00 €

Background: WEE1 is an evolutionarily conserved nuclear tyrosine kinase and a key regulator of the G2-M checkpoint phase of the cell cycle. WEE1 is responsible for the regulation of Cdk1/Cdc2 and phosphorylate the mammalian core histone H2B, thereby controlling entry into mitosis and DNA replication during S phase. Upon G2-M transition, in the absence of substantive DNA damage, polo-like kinase 1 (PLK1) phosphorylates WEE1, which targets WEE1 for degradation via the ubiquitin ligase complex. WEE1 is highly expressed in several cancer types, including hepatocellular carcinoma, breast cancers, cervical cancers, lung cancers. MK-1775, a developed pyrazolo-pyrimidine derivative, is a potent and selective small-molecule inhibitor of Wee1.

Recombinant human WEE1 protein kinase, amino acids Q250-Y646, N-terminally fused to GST-HIS6-Thrombin cleavage site, expressed in Sf9 cells

Theoretical MW : 74.9 kDa (fusion proteins)
Expression system: Baculovirus infected Sf9 cells
Purification: One-step affinity purification using glutathione agarose
Storage buffer: 50 mM Tris-HCl, pH 8.0; 100 mM NaCl, 5 mM DTT, 4 mM reduced glutathione, 20% glycerol
Protein concentration: 0.142 mg/ml (Bradford method using BSA as standard protein)
Method for determination of Km value & specific activity: Filter binding assay MSFC membrane
Specific activity: 2.000 pmol/mg x min 

Entrez Gene ID: 7465
UniProtKB: P30291

Ordering information: shipped on dry ice

Product specific literature:

Kiran Mahajan, Nupam P. Mahajan (2013) “WEE1 Tyrosine Kinase, A Novel Epigenetic Modifier” Trends Genet. 29(7): 394–402.
Matheson CJ, Backos DS1, Reigan P (2016) “Targeting WEE1 Kinase in Cancer.” Trends Pharmacol Sci.;37(10):872-881.
Schmidt M1, Rohe A2, Platzer C3, Najjar A4, Erdmann F5, Sippl W6.(2017)“ Regulation of G2/M Transition by Inhibition of WEE1 and PKMYT1 Kinases” Molecules. 23;22(12).